제일파마홀딩스

002620KOSPI회사 본부 및 경영 컨설팅 서비스업

53.0 / 100

Reference Date: 2026-07-24

Financial Score24.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue is on a declining trend. Rose 5.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharma Holdings was formed through a corporate split in 2017, operating as a holding company overseeing investments, while its subsidiary Jeil Pharmaceuticals focuses on pharmaceutical manufacturing and sales. Key subsidiaries include Jeil Health Sciences (general pharmaceuticals) and Jeil & Partners (sales agency), with major products such as Lipito, Lyrica, and Kepentec. The company's core businesses include management consulting, leasing, investment income, and pharmaceutical sales.

Number of Employees

40people

Average Salary

73.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

3.16Industry Average 5.326.5Point

Lower than industry avg (good)

PBR

0.23Industry Average 0.325.5Point

Lower than industry avg (good)

ROE

7.64Industry Average 4.075.5Point

1.9x industry avg (good)

Debt Ratio

18.01Industry Average 22.654.0Point

In line with industry avg

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲139.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 6,850Won52-week high 9,28052-week low 6,290

1-month return4.0Point

1m +5.55% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-15
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-15
Neutral주식등의대량보유상황보고서(일반)2026-07-15